contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
      id
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    pageUrl
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


novavax-to-host-conference-call-to-discuss-third-quarter-financial-and-operating-results-on-november-9-2020

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...

GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, November 9, 2020. Conference call details are as follows:<table style="border-collapse: collapse; width:70%; border-collapse:collapse ;"><tr><td style="max-width:30%; width:30%; min-width:30%;">Date:</td><td style="max-width:70%; width:70%; min-width:70%;">November 9, 2020</td></tr><tr><td>Time:</td><td>4:30 p.m. U.S. Eastern Time (ET)</td></tr><tr><td>Dial-in number:</td><td>(877) 212-6076 (Domestic) or (707) 287-9331 (International)</td></tr><tr><td>Passcode:</td><td>8059421</td></tr><tr><td>Webcast:</td><td><a href="http://www.novavax.com">www.novavax.com</a>, “For Investors”/ “Events”</td></tr></table>Conference call and webcast replay:<table style="border-collapse: collapse; width:70%; border-collapse:collapse ;"><tr><td style="max-width:30%; width:30%; min-width:30%;">Dates: </td><td style="max-width:70%; width:70%; min-width:70%;">Starting at 7:30 p.m. ET, November 9, 2020 until </td></tr><tr><td> </td><td>7:30 p.m. ET November 16, 2020</td></tr><tr><td>Dial-in number:</td><td>(855) 859-2056 (Domestic) or (404) 537-3406 (International)</td></tr><tr><td>Passcode:</td><td>8059421</td></tr><tr><td>Webcast:</td><td><a href="http://www.novavax.com">www.novavax.com</a>, “For Investors”/ “Events”, until February 9, 2021</td></tr></table>﻿About NovavaxNovavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is currently conducting multiple clinical trials for NVX-CoV2373, its vaccine candidate against the virus that causes COVID-19, including a pivotal Phase 3 clinical trial in the United Kingdom to evaluate the efficacy, safety and immunogenicity in individuals aged 18-84 years of age. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both candidate vaccines incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.For more information, visit <a href="https://www.globenewswire.com/Tracker?data=vPWbLayf5XMeDX4hkAzr2mZAEXdaGpRIcHnj69OIZ34BWa4aIDKhFMrLX7n8KujfHTCbNhTpCPMIKgzs1zK1Qg==">www.novavax.com</a> and connect with us on <a href="https://www.globenewswire.com/Tracker?data=QiFyJ2YyzdpT7-HVj1Yh36WezKv62AUn2XSQ1MbmQRlMP16ASPagpAdH1pLM24qK_27iiCz2W5rIg6VONXt8Vg==">Twitter</a> and <a href="https://www.globenewswire.com/Tracker?data=iQ2FbkoRjYJ9kiB8Pyp6foxKspGvioQogbX0H5bg0u1QLpccSyY4WKlfNrUz5D_ObOWyCs4QKkpnABMdZSVid-p-5yTd_k2cRmmR8407PEs=">LinkedIn</a>.Contacts: Investors Erika Trahan <a href="https://www.globenewswire.com/Tracker?data=dyn57dD0qC6s3JYjJJO2H9KpQsFpia0AE2cE_RTQUTbYq2PvYnhq4z8Ym5wPdqB8KyxwDzOqXO0vv-Hck--_cg==">ir@novavax.com</a> 240-268-2022Media Brandzone/KOGS Communication Edna Kaplan <a href="https://www.globenewswire.com/Tracker?data=-SvMmIM7mY5LzxNae6NS9oYRc59cvMib0YyHEVa8wv2M47Dno9mcEetymgToAB6X97K01YFbA59Oo6Ih51632g==">kaplan@kogspr.com</a> 617-974-8659 <img src="https://www.globenewswire.com/newsroom/ti?nf=ODA3ODM2MyMzODA2NzAyIzIwMTkwMzM=" width="1" height="1"/>

Novavax to Host Conference Call to Discuss Third Quarter Financial and Operating Results on November 9, 2020

Date:	November 9, 2020
Time:	4:30 p.m. U.S. Eastern Time (ET)
Dial-in number:	(877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode:	8059421
Webcast:	www.novavax.com, “For Investors”/ “Events”

Dates:	Starting at 7:30 p.m. ET, November 9, 2020 until
	7:30 p.m. ET November 16, 2020
Dial-in number:	(855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode:	8059421
Webcast:	www.novavax.com, “For Investors”/ “Events”, until February 9, 2021